Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTED in Moderate to Severe Thyroid Eye Disease
NCT02422368Phase 3Withdrawn
- Sponsor
- Iran University of Medical Sciences
- Start
- Sep 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ASTED in thyroid eye disease (TED), sponsored by Iran University of Medical Sciences. Planned start Sep 2022; status: withdrawn.
02
Drugs
ASTED
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT02422368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02422368.